A number of High Street chemists and private clinics sell and administer the Pfizer Covid vaccine directly to the public. The ...

More than 1,000 people who have sought support from the vaccine damage payment scheme after being injured or bereaved as a ...

researchers recommended that people who received it get a second booster dose with an mRNA vaccine such as Moderna and Pfizer. According to the published results, there were 129 coronavirus ...

There's one big difference though - Pfizer is seeking a green light for second booster dose of Comirnaty for people aged 60 and over and those in high-risk groups, while Moderna is going for a ...

Moderna has reported preliminary clinical ... Neutralising antibody titres against Omicron were doubled with the mRNA-1273.211 booster dose compared to the original SpikeVax booster at one and ...

The following is a summary of “Seroprevalence against SARS-CoV-2 after booster vaccination in a prison in Alicante (Spain),” published in the January 2025 issue of Infectious Disease by Montagud et al ...

A booster shot is an additional dose of a COVID-19 vaccine that enhances ... in the world due to agreements with Pfizer/BioNTech, Moderna, AstraZeneca, Medicago, Sanofi-GlaxoSmithKline, Novavax ...

The CDC did not provide the number of updated bivalent booster made by Jassen ... the rate of AEFIs following at least one dose of the Janssen vaccine was roughly twice as high as that observed with ...

Yet, uptake levels of vaccines in the US would tell a different story. As of mid-December, only 20.9 percent of adults in the ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence. The maker of vaccines, including the mRNA vaccine for COVID-19 ...

Moderna (MRNA) closed the latest trading day at $41.66, indicating a +0.6% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of 1.46%.

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech that'll never recover its former glory -- which it built on the success of ...